The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2022
|
| DOI | 10.3389/fphar.2021.785770 |
| Pubmed ID | |
| Authors |
Natalia Riva, Manuel Molina, Berta L. Cornaló, María V. Salvador, Andrea Savransky, Silvia Tenembaum, María M. Katsicas, Marta Monteverde, Paulo Cáceres Guido, Marcela Rousseau, Raquel Staciuk, Agustín González Correas, Pedro Zubizarreta, Oscar Imventarza, Eduardo Lagomarsino, Eduardo Spitzer, Marcelo Tinelli, Paula Schaiquevich |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 33% |
| Argentina | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 21 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 14% |
| Unspecified | 2 | 10% |
| Professor | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Researcher | 2 | 10% |
| Other | 1 | 5% |
| Unknown | 9 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 19% |
| Unspecified | 2 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Immunology and Microbiology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 10 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2022.
All research outputs
#13,770,210
of 23,347,114 outputs
Outputs from Frontiers in Pharmacology
#4,264
of 16,822 outputs
Outputs of similar age
#217,118
of 508,374 outputs
Outputs of similar age from Frontiers in Pharmacology
#259
of 1,206 outputs
Altmetric has tracked 23,347,114 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,822 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 508,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.
We're also able to compare this research output to 1,206 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.